Cencora rises after $1.1 billion EyeSouth retina deal

Shares of drug distributor Cencora COR.N rise 1.8% to $332.68 premarket

Co says it will buy EyeSouth Partners’ retina business in a deal valued at $1.1 billion, expanding its eye-care specialist network

Deal adds EyeSouth’s retina physicians to Cencora’s Retina Consultants of America, which manages eye doctors and clinics, co says

Says the acquisition is expected to slightly lift adjusted EPS in the first year after closing, even after financing costs

Co reaffirmed its fiscal 2026 forecast, noting it does not include the impact of the deal

Transaction is subject to regulatory approvals and customary closing conditions - COR

Shares up about 50% in 2025